UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
−Removed: On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $79.0 million (net of taxes, fees and commissions).
−Removed: On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300.0 million (net of taxes, fees and commissions).
−Removed: As of December 31, 2022, there was approximately $160.6 million (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program.
−Removed: The share repurchase program has no specified expiration date.
−Removed: Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans.
+Added: On May 3, 2023 our Board of Directors terminated the previous share repurchase program then in effect and authorized a new share repurchase program for the purchase of up to $500,000 (net of taxes, fees and commissions).
+Added: As of June 30, 2023, we have not made any repurchases under this share repurchase program.
+Added: This share repurchase program has no specified expiration date.
+Added: Under the May 3, 2023 authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans.
Any share repurchases may be activated, suspended or discontinued at any time.
−Removed: Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020.
−Removed: The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations .
−Removed: During the first nine months of fiscal 2023, we obtained 74,897 of our ordinary shares in the aggregate amount of $13.1 million in connection with share based compensation award programs.
−Removed: The following table summarizes the ordinary shares repurchase activity during the third quarter of fiscal 2023 under our ordinary share repurchase program:
+Added: During the first three months of fiscal 2024, we had no share repurchase activity pursuant to the previous share repurchase program or the May 3, 2023 authorization.
+Added: This does not include 5 shares purchased during the quarter at an average price of $195.47 per share by the STERIS Corporation 401(k) Plan on behalf of an executive officer of the Company who may be deemed to be an affiliated purchaser.
+Added: During the first three months of fiscal 2024, we obtained 51,494 of our ordinary shares in the aggregate amount of $8,724 in connection with share-based compensation award programs.
+Added: The following table summarizes the ordinary shares repurchase activity during the first quarter of fiscal 2024 under our ordinary share repurchase program:
Total Number of
−Removed: Shares Purchased (b)
+Added: Shares Purchased
Average Price Paid
−Removed: Per Share (c)
Total Number of
1 unchanged sentence
Part of Publicly
−Removed: Announced Plans (d)
+Added: Announced Plans
Maximum Dollar Value of Shares that May Yet Be Purchased Under the
Plans at Period End (in thousands)
−Removed: October 1-31 61,629 $ 169.38 61,629 $ 238,932
−Removed: November 1-30 25,000 181.59 25,000 234,392
−Removed: December 1-31 396,204 186.18 396,204 $ 160,626
+Added: April 1-30 — $ — — $ 13,932
+Added: May 1-31 — — — 500,000
+Added: June 1-30 — — — 500,000
Total — $ — — $ 500,000
−Removed: (1) Does not include 9 shares purchased during the quarter at an average price of $175.36 per share by the STERIS Corporation 401(k) Plan on behalf of an executive officer of the Company who may be deemed to be an affiliated purchaser.
−Removed: Exhibits required by Item 601 of Regulation S-K
−Removed: Exhibit Description
−Removed: 3.1 STERIS plc Amended Memorandum and Articles of Association (filed as Exhibit 3.1 to STERIS plc Form 10-K for the fiscal year ended March 31, 2019 (Commission File No.
−Removed: 001-38848), and incorporated herein by reference.)
−Removed: 15.1 Letter Re:
−Removed: Unaudited Interim Financial Information.
−Removed: 22.1 List of Guarantor Subsidiaries with respect to the 2.700% Notes due 2031 and 3.750% Notes due 2051 issued by STERIS Irish Finco Unlimited Company (filed as Exhibit 22.1 to Form 10-K for the fiscal year ended March 31, 2021 (Commission File No.
−Removed: 001-38848), and incorporated by reference).
−Removed: 31.1 Certification of the Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a).
−Removed: 31.2 Certification of the Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a).
−Removed: 32.1 Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: 101.SCH Inline Schema Document.
−Removed: 101.CAL Inline Calculation Linkbase Document.
−Removed: 101.DEF Inline Definition Linkbase Document.
−Removed: 101.LAB Inline Labels Linkbase Document.
−Removed: 101.PRE Inline Presentation Linkbase Document.
−Removed: 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: Vice President, Controller and Chief Accounting Officer
−Removed: February 8, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.